Category Celleron Therapeutics

UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.

Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Bill Fleming as its Chief Financial Officer. This appointment represents an important milestone for the company…

Oxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the grant of EU Orphan Drug Designation for Celleron’s lead compound CXD101 for peripheral T-cell lymphoma. On 8 November, 2017…

Oxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that it has signed Licensing and Co-development agreements for China and South Africa with Nuance Biotech, the Shanghai based…

Oxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that Dr Chris Towler is joining the Board of Directors as an Observer, appointed by the University of Oxford.…

Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the 3rd Shanghai International Forum for…

Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that Doug Manion M.D., FRCP(C) is joining the Board of Directors as a Non Executive Director, with immediate effect.…

Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that research on CXD101 its novel dual action HDAC inhibitor had been presented at the Inaugural Meeting of the…

Oxford 31st January 2017; Celleron Therapeutics Limited, the UK-based precision cancer medicines company, focussed on clinical trials of novel small molecule therapeutics, announced today that it has completed a new financing round with a consortium of South Korean investors. Celleron…